ClinicalTrials.gg
Active, not recruitingNCT04975464BRINKUpdated Nov 4, 2025

BRINK (BRain In Kidney Disease) Memory Study 2.0

An observational study in Chronic Kidney Diseases, Dementia and Dementia, Vascular, sponsored by Anne Murray. Active, not recruiting at 2 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-04.

Sponsored by Anne Murray · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
600
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
49th of 165
600 · median 125
Started
2011
with 47 others
Observational
167 of 988
44 open now
Primary completion
2026-05
later than 23 of 213 live
Registered
701st of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 49th largest by enrollment of the 165 observational ones that give a count, is one of 48 that started in 2011, is one of 167 observational ones, reaches primary completion later than 23 of the 213 other live ones, and was the 701st registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

In this study, the investigators will be looking at results of tests of memory and thinking and daily activities in a group of people without known chronic kidney disease (CKD) , and a group of CKD patients, and follow the participants for up to four more years, including after the participants start dialysis or receive a transplant. The investigators are doing this study to compare how often memory loss, confusion and difficulty with daily activities occur in those without and those with CKD. Additionally, the investigators are doing this study to identify risk factors for memory and thinking problems in CKD patients. The information received through the NDI will be utilized to help track our study population and help provide useful information regarding cause of death of those in our study.

Read the detailed description

Cognitive impairment (CI) in patients with pre-dialysis chronic kidney disease (CKD) is common, affecting more than five million older people with moderate to severe CKD (estimated glomerular filtration rate-eGFR \< 45). Both lower eGFR and increased albuminuria, a marker of systemic vascular endothelial function, are associated with increased dementia risk and structural MRI changes. Stroke prevalence is four times higher in advanced CKD than in non-CKD, and white matter hyperintensity (WMH) volume and cerebral atrophy are increased. Yet, the natural history, contributing factors, and brain abnormalities associated with cognitive decline in CKD are poorly understood. In addition, previous studies of CI in CKDthe investigators such as ADNI primarily included patients with mild CKD and lower risk of CI, and few have included longitudinal measures of CI. To fill these gaps, our multidisciplinary team (geriatrics, neurology, nephrology, neuroimaging) initiated the longitudinal BRain IN Kidney (BRINK) disease study. The investigators assembled a unique cohort of 433 CKD patients (\~20% mild-moderate; 35% advanced; 45% severe; eGFR \< 30), with mean eGFR of 34, and 141 non-CKD (eGFR ≥ 60) controls, followed the participants for a median of 2.5 years, and obtained baseline brain MRI, serial cognitive testing, and serum and urine biomarkers. Our primary goal is to extend BRINK and obtain three and five year brain MRIs to characterize cognitive decline and Alzheimer's disease and cerebrovascular-related MRI brain changes over five years. The investigators propose that CKD and its brain sequelae represent a model of accelerated cerebrovascular disease and brain aging, with high rates of hypertension (> 90%), diabetes (50%), inflammation, and oxidative stress-all factors known to contribute to both vascular dementia and Alzheimer's disease-driving parallel trajectories of microvascular endothelial dysfunction in the kidney and brain and secondary neurodegeneration. Our preliminary data demonstrate that at baseline those with eGFR \< 30 compared to eGFR ≥ 30 were almost twice as likely to have moderate-severe CI, and delayed memory was most affected, as seen in Alzheimer's disease. On brain MRI, the participants also had more strokes, WMH, and worse white matter integrity. In addition, the investigators found that the common CKD-related factors of elevated serum phosphorus and low hemoglobin were associated with worse cognitive function and more severe abnormalities on brain MRI. Our cross-sectional MRI findings support a cerebrovascular basis for CI in CKD, accelerated by CKD-related factors, together driving neurodegenerative changes that may serve as a proximate correlate of CI in CKD. Driven by our initial findings, the investigators seek to extend BRINK to define the relation between CKD severity and worsening MRI changes and cognitive decline, and the relation between the two. In addition, as the COVID pandemic has accelerated within the US with associated cerebrovascular, cognitive and CKD outcomes, the investigators will leverage this period to examine the effects of COVID diagnosis, symptoms and outcomes on cognitive decline and CKD progression. The investigators will measure these associations using a new COVID survey modeled after the COVID Symptom Tracker from Harvard. Specifically, the investigators propose the following longitudinal aims:

SPECIFIC AIMS (Note: all models will be adjusted for time-varying and time-invariant covariates) Aim 1 (total cohort): Characterize longitudinal changes in level of global cognitive function and cognitive domains over a mean of five years by eGFR level and examine COVID - 19 exposure as potential interaction.

Hypotheses 1: Those with eGFR \< 30 will be at greater risk of developing moderate/severe CI and decline in cognitive domain scores.

Aim 1a (CKD only): Estimate the associations between change in CKD-related factors and change in cognitive function in CKD over a mean of five years. Hypothesis 1a: Worsening CKD-related factors will be significantly associated with decline in global cognition and decline in cognitive domain scores.

Hypothesis 1b: COVID-19 exposure may modify and accelerate the relation between CKD progression and cognitive decline.

Aim 2 (MRI cohort): Determine the rate of cortical thinning, accumulation of WMHs, infarcts, change in WM integrity, and perfusion by eGFR levels over a mean of five years. Hypothesis 2: Frontotemporal cortical thinning (atrophy), increased cortical infarcts and WMH volume, and especially decreased global white matter integrity will progress more quickly with lower eGFR level.

Aim 2a (MRI cohort): Estimate the associations between CKD-related factors and structural and functional MRI changes over a mean of five years. Hypothesis 2a: Low hemoglobin and higher albuminuria will be associated with increased cortical thinning and decreased white matter integrity, and higher phosphorus with increased infarcts.

Aim 3 (MRI cohort): Measure the association between changes in structural and functional MRI and cognitive decline over a mean of five years. Hypothesis 3: Cortical thinning, increased WMH, infarcts, and worsening WM integrity and will be associated with decline in global cognition and cognitive domain scores.

This study is innovative by: a) mapping the longitudinal trajectories of imaging to longitudinal cognitive trajectories to measure the impact of CKD on brain changes, b) including the entire range of CKD enriched with advanced CKD, and c) applying a multidisciplinary approach. Our work is significant because it will inform the natural history of cognitive decline and associated brain pathology in CKD and their contributors. It will have impact by 1) identifying CKD patients at greatest risk for CI to alert clinicians, and the timing of potential interventions, 2) measuring the effect of high phosphorus and anemia on cognitive decline and brain changes, and 3) characterizing vascular and Alzheimer's disease brain changes in CKD.

METHODS Study Population Approximately 225 remaining BRINK CKD participants (eGFR \< 60; mean eGFR 34) using the CKD-EPI creatinine equation) and 100 age and race matched non-CKD patients with Stages 3-5 CKD (ages 50 and older will be followed in-person, by telephone, or by medical records at the following locations: Hennepin Healthcare clinics, HealthPartners clinics, the University of Minnesota - Fairview Clinics, and/or the Minneapolis Veterans Affairs Medical Center (MVAMC).

Study Measures

  1. A screening interview will be conducted via telephone to determine eligibility (using criteria listed below) to continue to participate in BRINK 2.0 when scheduling the first visit.
  2. All BRINK 2.0 participants will continue to be classified as CKD (GFR \< 60 ml/min/1.73m2) or non- CKD controls (eGFR ≥ 60 ± 5 ml/min/1.73 m2) based on their initial classification at their baseline visit.
  3. At the initial and three subsequent annual face-to-face visits, the medical history interview and questionnaires, cognitive testing, and physical function assessment will take approximately 75-90 minutes.
  4. If the participant scores \< 78 on 3MSE or \< 18 on MOCA, an informant interview is triggered either in-person or by telephone to assess the participant's risk of MCI or dementia. The informant interview will be conducted with the Functional Assessment Questionnaire (FAQ) instrument. If no informant is available, conduct the UPSA performance-based assessment with the participant at the same time as current visit.
  5. A structured telephone interview will be conducted at intervening six months with brief questionnaires.
  6. If the participant has missed their last annual visit, the participant will be scheduled for a face-to-face visit at six months ± two months from their last scheduled annual visit with cognitive battery two (from previous six month visits, and using MOCA instead of 3MS).
  7. If a participant is unable to attend an annual face to face visit, the TICS cognitive phone test will be conducted within ± 2 months instead of their scheduled face-to-face annual visit.
  8. If the participant initiates any modality of dialysis, or undergoes renal transplant, a follow-up visit will be scheduled as soon as possible. The participant will then continue to be seen at six month intervals from the initial post dialysis visit. For the dialysis or transplant patients, at 6, 18, and 30 month follow-up visits, a person identified as the participant's informant will be interviewed with the ADCS- IADL to assess the participant's functional status and dementia status.
  9. For the subset of non-dialysis / transplant subjects who received a baseline MRI, a three year and five year follow-up MRI will be obtained if still within their three month window from previous respective annual visit. If a participant has missed their 3 year and/or 5 year MRI, additional MRIs should be obtained following their 4th, 6th, 7th, or 8th year visit in order to obtain a total of a maximum of three MRIs. Follow up MRIs need to be completed with a two year gap in-between each MRI.
  10. An MRI will also be obtained within 90 days after dialysis initiation and then at 1 year and annually thereafter for a maximum of 5 MRI's after dialysis initiation, each with a 90 day window from their in person visit..
  11. Laboratory measures: renal panel (sodium, potassium, chloride, carbon dioxide, anion gap, albumin, calcium, creatinine, phosphorus, glucose, blood urea nitrogen, eGFR), hemoglobin, hemoglobin A1c, urine albumin, urine microalbumin/creatinine ratio, creatinine, and lipid panel will be collected at baseline and annually.
  12. Research biomarker labs: serum and plasma for cystatin C, IL-6 in serum, IL-6 in urine, TNFα receptor-1, 8-isoprostane, parathyroid hormone, 25-OH vitamin D, advanced glycation end products, clusterin, asymmetric dimethylarginine (ADMA). were obtained at baseline BRINK 1 visit, and at the 3 year annual visit, or if missed then, at the next in- person BRINK 2 visit. If research labs are unable to be obtained during the first BRINK 2.0 in person visit, the sample will be collected at the next annual in person visit.
03

Conditions studied

  • Chronic Kidney Diseases
  • Dementia
  • Dementia, Vascular
  • Stroke
  • Alzheimer Disease
  • Cognitive Decline
  • Cognitive Impairment
  • Cognitive Dysfunction
  • Kidney Diseases
  • Diabetes
  • Cerebral Atrophy
  • Small Vessel Ischemic Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All potential participants must be previous BRINK participants

Eligibility criteria

Inclusion Criteria for CKD Participants:

  1. In stages 3b-5 of chronic kidney disease ( ≤ 60 ± 5 ml/min/1.73m2) at the first baseline visit in BRINK 1.0.
  2. Able to complete an approximately 90 minute cognitive and physical testing battery.
  3. Able to sign the , or allow a caregiver, relative, surrogate, or witness to sign the informed consent if participant is unable to do so.

Inclusion Criteria for non-CKD Participants:

  1. GFR ≥ 60 ± 5 ml/min/1.73m2 at the first baseline visit in BRINK 1.0.
  2. Able to complete an approximately 90 minute cognitive and physical testing battery.
  3. Able to sign the informed consent, or allow a caregiver, relative, surrogate, and/or witness to sign the informed consent if participant is unable to do so.

Exclusion Criteria:

Exclusion Criteria for CKD and non-CKD Participants:

  1. Acute psychiatric illness that would impede cognitive testing
  2. Active chemical dependence
  3. Legally blind or unable to complete cognitive tests due to visual loss or deafness
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
600 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Control

    eGFR ≥ 60 ± 5 ml/min/1.73m2 at the first baseline visit in BRINK 1.0. Non-CKD population.

  • Mild CKD

    eGFR 45 - \<60

  • CKD

    eGFR \< 45

  • Dialysis/Transplant

    active dialysis for dialysis participants or kidney transplant for transplant participants

06

What researchers measure

Primary outcomes

  1. Screening Interview

    A screening interview will be conducted via telephone to determine eligibility (using criteria listed below) to continue to participate in BRINK 2.0 when scheduling the first visit.

    Time frame: 5 years

  2. Classification

    All BRINK 2.0 participants will continue to be classified as CKD (GFR \< 60 ml/min/1.73m2) or non- CKD controls (eGFR ≥ 60 ± 5 ml/min/1.73 m2) based on their initial classification at their baseline visit.

    Time frame: 5 years

  3. Medical History Interview

    At the initial and three subsequent annual face-to-face visits, the medical history interview and questionnaires, cognitive testing, and physical function assessment will take approximately 75-90 minutes

    Time frame: 5 years

  4. Informant Interview

    If the participant scores \< 88 on 3MSE or \< 18 on MOCA, an informant interview is triggered either in-person or by telephone to assess the participant's risk of MCI or dementia. The informant interview will be conducted with the Functional Assessment Questionnaire (FAQ) instrument. If no informant is available, conduct the UPSA performance-based assessment with the participant at the same time as current visit.

    Time frame: 5 years

  5. Structured Telephone Interview

    A structured telephone interview will be conducted at intervening six months with brief questionnaires.

    Time frame: 5 years

  6. Missed Visits

    If the participant has missed their last annual visit, they will be scheduled for a face-to-face visit at six months ± two months from their last scheduled annual visit with cognitive battery two (from previous six month visits, and using MOCA instead of 3MS).

    Time frame: 5 years

  7. TICS

    If a participant is unable to attend an annual face to face visit, the TICS cognitive phone test will be conducted within ± 2 months instead of their scheduled face-to-face annual visit.

    Time frame: phone visit

  8. Dialysis/Transplant baseline

    If the participant initiates any modality of dialysis, or undergoes renal transplant, a follow-up visit will be scheduled as soon as possible. The participant will then continue to be seen at six month intervals from the initial post dialysis visit. For the dialysis or transplant patients, at 6, 18, and 30 month follow-up visits, a person identified as the participant's informant will be interviewed with the ADCS- IADL to assess the participant's functional status and dementia status

    Time frame: 5 years

  9. Follow Up MRI

    For the subset of non-dialysis / transplant subjects who received a baseline MRI, a three year and five year follow-up MRI will be obtained if still within their three month window from previous respective annual visit. If a participant has missed their 3 year and/or 5 year MRI, additional MRIs should be obtained following their 4th, 6th, 7th, or 8th year visit in order to obtain a total of a maximum of three MRIs. Follow up MRIs need to be completed with a two year gap in-between each MRI.

    Time frame: 5 years

  10. Dialysis MRI

    An MRI will also be obtained within 90 days after dialysis initiation and then at 1 year and annually thereafter for a maximum of 5 MRI's after dialysis initiation, each with a 90 day window from their in person visit..

    Time frame: 5 years

  11. Lab Measures

    Laboratory measures: renal panel (sodium, potassium, chloride, carbon dioxide, anion gap, albumin, calcium, creatinine, phosphorus, glucose, blood urea nitrogen, eGFR), hemoglobin, hemoglobin A1c, urine albumin, urine microalbumin/creatinine ratio, creatinine, and lipid panel will be collected at baseline and annually.

    Time frame: 5 years

  12. Research Biomarker labs

    Research biomarker labs: serum and plasma for cystatin C, IL-6 in serum, IL-6 in urine, TNFα receptor-1, 8-isoprostane, parathyroid hormone, 25-OH vitamin D, advanced glycation end products, clusterin, asymmetric dimethylarginine (ADMA). were obtained at baseline BRINK 1 visit, and at the 3 year annual visit, or if missed then, at the next in- person BRINK 2 visit. If research labs are unable to be obtained during the first BRINK 2.0 in person visit, the sample will be collected at the next annual in person visit.

    Time frame: 1 year

  13. COVID 19 survey

    Starting April 10, 2020, The COVID Survey will be added to the BRINK Subject Interview administered at every annual visit (by phone or in person) and to every six month interview phone visit, starting with their next scheduled visits.for up to two years.

    Time frame: 5 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2011 (actual). Primary completion is estimated for May 2026, 174 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Jul 23, 2021
StartActual
Nov 15, 2011
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04975464
Lead sponsor
Anne Murray
Collaborators
National Institute on Aging (NIA), Minneapolis Veterans Affairs Medical Center, Mayo Clinic, HealthPartners Institute
Responsible party
Anne Murray (Medical Director, Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute) — Sponsor-investigator
First posted
Jul 23, 2021
Start date
Nov 15, 2011
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Nov 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion